Nexium, a popular drug used to treat gastroesophageal reflux disease, will be removed from TRICARE's formulary list. Effective June 28, 2017, the drug will no longer be available in military hospitals and clinics and those patients who choose to remain on the drug will pay increased fees. The change comes because the drug's producer, biopharmaceutical company AstraZeneca, cancelled the Department of Defense's 10-year Nexium preferred pricing agreement on April 1. The increased price is costing the DOD an additional $1.6 million per day. The almost 338,000 TRICARE patients currently prescribed Nexium are advised to contact their doctors to determine if Nexium is medically necessary or if they can safely be switched to an alternative drug. Patients taking Nexium should receive letters from the Defense Health Agency with more details. Read more about alternatives and costs.